A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis
Bruton's tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple
sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which …
sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which …
Population pharmacokinetics, efficacy exposure-response analysis, and model-based meta-analysis of fenebrutinib in subjects with rheumatoid arthritis
P Chan, J Yu, L Chinn, M Prohn, J Huisman… - Pharmaceutical …, 2020 - Springer
Abstract Purpose Fenebrutinib (GDC-0853), a Bruton's tyrosine kinase (BTK) inhibitor was
investigated in a Phase 2 clinical trial in patients with rheumatoid arthritis (RA). Our aim was …
investigated in a Phase 2 clinical trial in patients with rheumatoid arthritis (RA). Our aim was …